June 18, 2021
Business News

A neoantigen pioneer says its tech is working great. So what wrecked the share price? – Endpoints News

Four months ago, one of the favorite talking points on the biopharma social media wave length was whether Moderna shares $MRNA were priced right or were wildly inflated.
After all, said the naysayers, the company had never actually pushed a treatment to an approval. Did messenger RNA really work, coding cells to make a drug or a vaccine? And how about all that chatter about how secretive they are, or were?
Now, as CEO Stéphane Bancel and the top execs push the company to the forefront of a frantic race to develop the first vaccine to fight against the reignited wildfire spread of Covid-19, all those questions have been magnified along with the stock price.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.

Click here to view the original article.

Related Posts

You might also like ...

AON Splash Image
Aura Biosciences Assembles New Bladder Cancer Focused Scientific Advisory Board
AON Splash Image
Immunome Appoints Franklyn G. Prendergast, M.D., Ph.D., to Board of Directors
Sema4 Appoints Andrew Kasarskis, Health Data Expert and Precision Medicine Scientist, as Chief Data Officer